Premium IOL Guide Australia 2026: Multifocal, EDOF, and Enhanced Monofocal Lenses Explained

Choosing a premium intraocular lens (IOL) is one of the most consequential decisions in cataract surgery and refractive lens exchange. The range of lenses available in Australia has expanded significantly in recent years, and the differences between categories, and between lenses within the same category, are clinically meaningful. This guide covers every major premium lens category available in Australia in 2026, with individual profiles of the lenses most commonly used in Australian surgical practice, a comparison of their optical principles, visual outcomes, and dysphotopsia profiles, and guidance for patients and optometrists on how lens selection decisions are made.

Understanding the IOL categories

Before comparing individual lenses, it helps to understand the four main categories available in Australia. All are implanted using the phacoemulsification technique used in modern lens surgery. These categories differ fundamentally in how they handle light and what visual outcomes they target. For a general overview of IOL options for cataract surgery, see our dedicated guide.

Enhanced monofocal lenses, also called monofocal-plus, correct vision at one primary focal distance but with a modest extension of depth of focus, typically adding 0.5 to 1.5 dioptres of range beyond a standard monofocal. They maintain a dysphotopsia profile essentially identical to a standard monofocal, meaning minimal halos or glare at night. Reading glasses are still required for most near tasks.

EDOF lenses (extended depth of focus) extend the focal range from distance to intermediate, typically providing 1.5 to 2.0 dioptres of additional range. True EDOF lenses meet the ANSI criteria for this classification, which requires significantly better distance-corrected intermediate acuity than a monofocal. EDOF lenses produce fewer halos and glare than multifocal lenses but more than enhanced monofocals, particularly diffractive designs. Reading glasses are usually still needed for fine near tasks.

Full range of vision lenses, including trifocals and hybrid multifocal-EDOF designs, aim to provide functional vision across distance, intermediate, and near, offering the highest level of spectacle independence. They achieve this through diffractive optics that split light across multiple focal zones. The trade-off is a higher incidence of halos and glare, particularly around point sources of light at night. Patient selection and pre-operative counselling are critical for this category.

The mix-and-match approach involves implanting different lens types in each eye. This is discussed separately below, with important caveats about the current evidence base.

Comparison table

Clareon PanOptix Pro (Alcon)

The Clareon PanOptix Pro is the latest iteration of the most widely implanted trifocal IOL in the world. It replaces the original AcrySof PanOptix on the Clareon hydrophobic acrylic platform, which produces virtually no glistenings and has a low rate of posterior capsule opacification. The Pro version uses ENLIGHTEN NXT optical technology, increasing light utilisation from 88 percent in the original PanOptix to 94 percent, reducing light scatter and improving contrast.

The lens delivers three focal points targeting distance, approximately 60cm for intermediate computer work, and approximately 40cm for reading. It is the lens of choice for patients who prioritise spectacle independence above all other considerations and who have realistic expectations about nighttime halos during the neuroadaptation period, typically three to six months.

Optical design: Diffractive, 94 percent light utilisation with ENLIGHTEN NXT technology.

Visual range: Distance, intermediate, near.

Dysphotopsia profile: Moderate halos and glare around point light sources, improved compared with original PanOptix. Studies show approximately 69 to 80 percent of patients report little to no halos at six months.

Best suited to: Patients highly motivated for spectacle independence, who spend significant time reading, and who can tolerate and adapt to mild nighttime halos during the adaptation period.

Less suited to: Frequent night drivers, patients with large pupils in dim light, patients with dry eye that has not been optimised prior to surgery, patients with any macular pathology, patients with unrealistic expectations about visual side effects.

Toric version: Clareon PanOptix Pro Toric.

Clareon Vivity (Alcon)

The Clareon Vivity is the leading non-diffractive EDOF lens available in Australia and one of the most commonly implanted premium lenses globally. It uses Alcon's X-WAVE wavefront-shaping technology, which involves two smooth transition zones on the anterior surface that shift and extend the wavefront rather than splitting light into discrete focal zones. The result is a continuous range of vision from distance to intermediate with a dysphotopsia profile approaching that of a standard monofocal lens.

The Clareon platform material produces minimal glistenings. Most metropolitan cataract theatres in Australia maintain Vivity in regular stock.

Optical design: Non-diffractive, X-WAVE wavefront-shaping.

Visual range: Distance to intermediate, with functional near vision in well-illuminated conditions. Reading glasses are usually needed for fine print.

Dysphotopsia profile: Closest to monofocal of all EDOF lenses. Studies show 85 percent of patients report little to no halos or glare at one month, compared with 69 percent for PanOptix in the same study.

Best suited to: Patients who want good distance and intermediate vision with minimal night-vision disturbance, particularly active patients, frequent drivers, and those with high visual demands in dim light. May be appropriate for patients with mild macular pathology where diffractive multifocal optics are contraindicated, though this requires individual assessment.

Less suited to: Patients who require spectacle independence for fine near tasks such as reading small print or prolonged close work.

Toric version: Clareon Vivity Toric.

TECNIS PureSee (Johnson and Johnson Vision)

The TECNIS PureSee is a purely refractive EDOF lens that has been available in Australia since 2024. It achieved FDA approval in March 2026, making it one of the most recently approved EDOF lenses globally. Uniquely, its pivotal clinical trial was conducted in Australia and New Zealand, providing a particularly relevant evidence base for Australian practice.

PureSee uses a continuously varying posterior curvature to achieve extended depth of focus without diffractive optics. The anterior surface is wavefront-designed to compensate for corneal spherical aberration. It is the first EDOF lens to receive FDA approval without a labelling warning regarding loss of contrast sensitivity.

The Australian and New Zealand clinical study showed PureSee achieved statistically better distance-corrected intermediate acuity (0.13 vs 0.18 logMAR) and distance-corrected near acuity (0.37 vs 0.43 logMAR) compared with TECNIS Eyhance, with comparable contrast sensitivity and dysphotopsia profiles. Over 95 percent of patients reported no very bothersome visual disturbances.

Optical design: Purely refractive, continuously varying posterior curvature, aspheric anterior surface.

Visual range: Distance, intermediate, functional near.

Dysphotopsia profile: Monofocal-like. In the Australian and New Zealand study, 91.7 percent of patients reported no or minimal halos, 95 percent reported no or minimal starbursts, and 95 percent reported no or minimal glare.

Best suited to: Patients who want better intermediate and near vision than an enhanced monofocal provides, with a dysphotopsia profile suitable for night driving. A useful option for patients who are borderline candidates for a full trifocal due to night vision concerns or occupation.

Toric version: TECNIS PureSee Toric II.

TECNIS Odyssey (Johnson and Johnson Vision)

The TECNIS Odyssey is the current generation full-range IOL from Johnson and Johnson Vision, replacing the TECNIS Synergy in many clinical settings. It uses a freeform diffractive profile designed to deliver a continuous range of vision from distance to near with an improved dysphotopsia profile and low-light image quality benchmark compared with its predecessor.

The Odyssey is part of the TECNIS InteliLight platform, sharing material and design principles with PureSee, making the two a well-matched combination for patients considering a mix-and-match approach within the same platform. However, see the caveat below regarding the current evidence base for mix-and-match strategies.

Optical design: Diffractive freeform profile, full range of vision.

Visual range: Continuous from distance through near.

Dysphotopsia profile: Optimised compared with Synergy. Adaptation typically occurs within three to six months.

Best suited to: Patients who want maximum spectacle independence including for close reading and are prepared to accept the adaptation period associated with diffractive optics.

Toric version: Yes.

TECNIS Synergy (Johnson and Johnson Vision)

The TECNIS Synergy combines EDOF echelette technology with multifocal diffractive optics to deliver a continuous range of vision from distance to near. It blends the range of an EDOF with the near addition of a trifocal. The Synergy has been largely succeeded by the Odyssey in Australian practice but remains available and in use.

The Synergy uses InteliLight technology including a violet-light filter and achromatic design. Its near addition is stronger than the PanOptix, making it particularly suited to patients with very high near vision demands.

Optical design: Diffractive echelette combined with multifocal diffractive optics.

Visual range: Continuous from distance to near, stronger near addition than PanOptix.

Dysphotopsia profile: Moderate halos comparable to other full-range lenses.

Best suited to: Patients who prioritise near reading vision above all other considerations and who can tolerate the associated nighttime adaptation period.

TECNIS Eyhance (Johnson and Johnson Vision)

The TECNIS Eyhance is the most widely used enhanced monofocal lens in Australia. It uses a central power gradient of approximately +0.5 dioptres to provide a modest extension of depth of focus compared with a standard monofocal, with a dysphotopsia profile indistinguishable from a monofocal lens. It does not meet the ANSI criteria for classification as a true EDOF lens, but it reliably provides better uncorrected intermediate acuity than a standard monofocal in most patients.

The Eyhance is particularly useful in eyes with previous myopic LASIK, where its negative spherical aberration design counteracts the positive spherical aberration introduced by the prior laser treatment.

Optical design: Central power gradient, negative spherical aberration.

Visual range: Distance, enhanced intermediate. Reading glasses required for most near tasks.

Dysphotopsia profile: Identical to standard monofocal. No increase in halos, glare, or starbursts.

Best suited to: Patients who want the most reliable optical quality and night-vision safety with a modest improvement in intermediate vision. Suitable for eyes with previous LASIK, mild macular pathology, dry eye, or other factors that contraindicate diffractive optics.

Toric version: TECNIS Eyhance Toric II.

Rayner RayOne EMV (Rayner)

The RayOne EMV (Enhanced Monovision) was developed in collaboration with Professor Graham Barrett and uses a positive spherical aberration design to extend the depth of focus, providing up to 1.5 dioptres of additional range. Unlike the Eyhance, which uses negative spherical aberration, the EMV's positive spherical aberration approach is a distinct optical strategy for achieving enhanced intermediate vision.

Professor Barrett is the developer of the Barrett Universal II formula, which is the most widely used IOL power calculation formula in Australian practice, lending particular credibility to the optical design philosophy behind this lens.

Optical design: Positive spherical aberration.

Visual range: Distance, enhanced intermediate, up to 1.5D additional range.

Dysphotopsia profile: Minimal, comparable to a standard monofocal.

Best suited to: Patients who want extended intermediate vision with a monofocal-equivalent night vision profile. Australian surgeons report good distance acuity outcomes with minimal dysphotopsias.

Toric version: RayOne EMV Toric.

BVI FineVision POD F (BVI Medical)

The FineVision POD F is a trifocal IOL that concentrates its diffractive optics in the central 4.5mm optical zone, with the outer zone behaving more like a monofocal. When the pupil dilates in dim light, more light passes through the peripheral monofocal zone, which reduces the intensity of peripheral halos compared with full-field diffractive trifocals. It is a hydrophilic acrylic lens, differing from the hydrophobic platforms used by Alcon and Johnson and Johnson.

Optical design: Trifocal diffractive, central 4.5mm zone, monofocal-like periphery.

Visual range: Distance, intermediate, near.

Dysphotopsia profile: Reduced peripheral halos compared with full-field diffractive trifocals due to the peripheral monofocal zone. May be advantageous for patients with concerns about night driving who still want near independence.

Toric version: Yes.

How lens selection decisions are made in clinical practice

No premium lens is appropriate for every patient. The selection process involves a combination of objective measurements and subjective assessment of the patient's visual goals, lifestyle, and tolerance for visual side effects.

The objective factors assessed before lens selection include visual acuity and refraction, corneal topography to assess corneal regularity and astigmatism, macular OCT to rule out significant macular pathology, pupil size in mesopic conditions as large pupils increase dysphotopsias with diffractive lenses, anterior chamber depth, and biometry for lens power calculation.

The subjective factors that guide category selection are the patient's dominant visual activities, their tolerance for an adaptation period associated with diffractive lenses, whether they drive frequently at night, their near vision demands, their occupation, and how strongly they want to minimise dependence on glasses.

A useful clinical framework considers three patient profiles. The first is the patient who wants maximum spectacle independence and accepts that an adaptation period is required. This patient is a candidate for a trifocal or full-range lens such as PanOptix Pro or Odyssey. The second is the patient who wants better intermediate vision than a monofocal and does not want to risk nighttime visual disturbance. This patient is suited to a non-diffractive EDOF such as Vivity or PureSee. The third is the patient who values optical quality and night-vision safety above spectacle independence, or who has complicating factors such as previous LASIK, mild macular disease, or dry eye. This patient is best served by an enhanced monofocal such as Eyhance or EMV, with monovision targeting if near vision is a priority.

For an overview of what to expect in the weeks after surgery, including drop regimen and vision stabilisation timeline, see our cataract surgery recovery guide.

Contraindications to premium diffractive IOLs

Patients who are not appropriate candidates for diffractive multifocal or EDOF lenses include those with significant macular pathology such as macular degeneration, epiretinal membrane, or diabetic macular oedema, those with irregular corneas from keratoconus or previous corneal surgery where precise lens power calculation is not achievable, those with severe dry eye that has not been optimised prior to surgery, patients with occupations requiring the highest level of night vision such as commercial pilots, and patients with unrealistic expectations or high levels of pre-operative anxiety about visual side effects.

In these patients, enhanced monofocal lenses or standard monofocal lenses with a targeted monovision approach are more appropriate.

The mix-and-match approach: possibilities and limitations

Implanting different lens types in each eye has attracted significant interest as a strategy for achieving a broader visual range while limiting the dysphotopsias associated with bilateral trifocal implantation. The most commonly discussed approach is to combine a non-diffractive EDOF in the dominant eye with a trifocal in the non-dominant eye.

However, it is important to be clear about the current evidence base. Mix-and-match IOL implantation is not well studied in high-quality randomised controlled trials. Most available evidence comes from case series, retrospective studies, and expert opinion. While outcomes in published series have generally been favourable, the optimal combinations, patient selection criteria, and long-term outcomes have not been established with the rigour that characterises the evidence base for bilateral implantation of a single lens type.

The rationale for mix-and-match approaches is sound: the dominant eye receives a lens with the lowest dysphotopsia profile, providing reliable distance and night driving vision, while the non-dominant eye receives a trifocal contributing near and reading vision. With both eyes open, the brain integrates the visual input to provide a functional range with potentially fewer halos than bilateral trifocal implantation.

When mix-and-match strategies are considered, most experienced surgeons recommend keeping lenses within the same optical platform where possible. Within the Alcon Clareon platform, Vivity and PanOptix Pro share the same material, edge design, chromophore, and A-constant. Within the Johnson and Johnson TECNIS platform, PureSee and Odyssey share the InteliLight platform. The rationale is that matching optical platforms may improve binocular integration, though direct comparative evidence for this principle is limited.

Mix-and-match approaches should be discussed with patients as a strategy based on available evidence and clinical experience rather than a well-established standard of care, and the decision should be individualised based on the patient's specific visual goals and circumstances.

A note for optometrists referring patients for premium IOL consultation

The most valuable information an optometrist can provide in a premium IOL referral is the patient's visual goals and daily visual demands, whether they drive frequently at night, macular health on OCT, the quality of the ocular surface and tear film, and any history of previous corneal surgery.

Patients with dry eye should ideally have their ocular surface optimised before the pre-operative IOL assessment, as a compromised tear film affects corneal topography measurements and biometry accuracy.

It is appropriate to counsel patients that premium lens selection is an individualised clinical decision. The right lens for one patient is not the right lens for another, and the consultation is a conversation about visual goals rather than a product selection exercise.